|
Sign In to gain access to subscriptions and/or personal tools.
|
Fatigue associated with multiple sclerosis: diagnosis, impact and management
Rohit Bakshi
Buffalo Neuroimaging Analysis Center and William C Baird Multiple Sclerosis Research Center, The Jacobs Neurological Institute, University at Buffalo, State University of New York, Buffalo, New York, USA, rbakshi{at}buffalo.edu
In patients with multiple sclerosis (MS) fatigue is the most common symptom and one of the most disabling features. A s many as 40% have described it as the single most disabling symptom - a higher percentage than weakness, spasticity, motor problems, or bowel or bladder problems. The etiology and patho physiology of MS-related fatigue remain unknown. Studies have failed to demonstrate an association between MS-related fatigue and the level of disability, clinical disease subtype, or gender, although recent data show an association between MS-related fatigue and depression and quality of life. Imaging studies using positron emission tomography suggest that fatigue in MS is related to hypometabolism of specific brain areas, including the frontal and subcortical circuits. The impact of fatigue on patient functioning and quality of life clearly warrants intervention. In addition to nonpharmacologic measures, such as exercise and energy conservation strategies, several pharmacologic agents have been evaluated for their ability to reduce MS-related fatigue, including amantadine, central nervous system stimulants (pemoline), and the novel wake-promoting agent modafinil.
Key Words: amantadine • fatigue • magnetic resonance imaging • modafinil • multiple sclerosis • pemoline • positron emission tomography • quality of life
Multiple Sclerosis, Vol. 9, No. 3,
219-227 (2003)
DOI: 10.1191/1352458503ms904oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Patti, M. Pia Amato, S. Bastianello, L. Caniatti, E. Di Monte, F. Lijoi, B. Goretti, S. Messina, O. Picconi, M. R. Tola, et al.
Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing--remitting multiple sclerosis: 2-year results from the COGIMUS study
Therapeutic Advances in Neurological Disorders,
March 1, 2009;
2(2):
67 - 77.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Sepulcre, J. Masdeu, J Goni, G Arrondo, N Velez de Mendizabal, B Bejarano, and P Villoslada
Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways
Multiple Sclerosis,
March 1, 2009;
15(3):
337 - 344.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. A. Cohen
Identification, causation, alleviation, and prevention of complications (ICAP): An approach to symptom and disability management in multiple sclerosis
Neurology,
December 9, 2008;
71(24_suppl_3):
S14 - S20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Amato, B. Goretti, A. Ghezzi, S. Lori, V. Zipoli, E. Portaccio, L. Moiola, M. Falautano, M. F. De Caro, M. Lopez, et al.
Cognitive and psychosocial features of childhood and juvenile MS
Neurology,
May 13, 2008;
70(20):
1891 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sauter, K. Zebenholzer, J. Hisakawa, J. Zeitlhofer, and K. Vass
A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients
Multiple Sclerosis,
May 1, 2008;
14(4):
500 - 505.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx
Origin of Fatigue in Multiple Sclerosis: Review of the Literature
Neurorehabil Neural Repair,
February 1, 2008;
22(1):
91 - 100.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As
Fatigue in palliative care patients -- an EAPC approach
Palliative Medicine,
January 1, 2008;
22(1):
13 - 32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U. Dalgas, E. Stenager, and T. Ingemann-Hansen
Review: Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training
Multiple Sclerosis,
January 1, 2008;
14(1):
35 - 53.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Debouverie, S. Pittion-Vouyovitch, S. Louis, and F. Guillemin
Validity of a French version of the fatigue impact scale in multiple sclerosis
Multiple Sclerosis,
September 1, 2007;
13(8):
1026 - 1032.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Benito-Leon, P. Martinez-Martin, B. Frades, M.L. Martinez-Gines, C. de Andres, J.E. Meca-Lallana, A.R. Antiguedad, B. Huete-Anton, E. Rodriguez-Garcia, and J. Ruiz-Martinez
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS)
Multiple Sclerosis,
June 1, 2007;
13(5):
645 - 651.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Tellez, M. Comabella, E v. Julia, J. Rio, M a. Tintore, L. Brieva, C. Nos, and X. Montalban
Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone
Multiple Sclerosis,
August 1, 2006;
12(4):
487 - 494.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Mostert and J. Kesselring
Effect of pulsed magnetic field therapy on the level of fatigue in patients with multiple sclerosis - a randomized controlled trial
Multiple Sclerosis,
June 1, 2005;
11(3):
302 - 305.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. V Kalia and P. W OConnor
Severity of chronic pain and its relationship to quality of life in multiple sclerosis
Multiple Sclerosis,
June 1, 2005;
11(3):
322 - 327.
[Abstract]
[PDF]
|
|
|
|
|
